Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 7:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Liothyronine, Sodium Clear all
Active, not recruiting Phase 2 Interventional

Treatment of ARDS With Instilled T3

NCT04115514
View directory record Official record
Conditions
ARDS, Human, Lung, Wet, Thyroid, Pulmonary Edema, Lung Inflammation
Interventions
Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation., Non-intervention
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Edina, Minnesota • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 28, 2026, 7:29 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Desiccated Thyroid Extract Versus Synthetic T3/T4 Combination (ThyrolarTM) Versus L-T4 Alone in the Therapy of Primary Hypothyroidism With Special Attention to the Gene Polymorphism

NCT02317926
View directory record Official record
Conditions
Hypothyroidism
Interventions
Levothyroxine, Levothyroxine Plus Liothyronine, Desiccated Thyroid Extract
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
1
States / cities
Besthesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 2 Interventional Results available

Energy Metabolism in Thyroidectomized Patients

NCT04782856
View directory record Official record
Conditions
Thyroid Goiter, Hypothyroidism, Thyroid Cancer
Interventions
Levothyroxine, Liothyronine, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 89 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Sep 28, 2026, 7:29 AM EDT
Recruiting Phase 1Phase 2 Interventional

Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease

NCT07346157
View directory record Official record
Conditions
Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma Recurrent
Interventions
Liothyronine (L-T3), Bevacizumab, Irinotecan, Temozolomide (TMZ)
Drug
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
1 Year to 25 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
San Francisco, California • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 1 Interventional

Open-label Study of Liothyronine in MS

NCT02506751
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
Interventions
liothyronine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 58 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2018 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 2 Interventional

A Study of T3 Therapy in Patients With Hypothyroidism

NCT01800617
View directory record Official record
Conditions
Hypothyroidism
Interventions
Liothyronine, Sodium
Drug
Lead sponsor
Ipe, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 3 Interventional

Study of Triostat in Infants During Heart Surgery

NCT00027417
View directory record Official record
Conditions
Heart Defects, Congenital
Interventions
Liothyronine sodium/triiodothyronine, Cardiopulmonary bypass and cardiac surgery
Drug · Procedure
Lead sponsor
Michael Portman
Other
Eligibility
Up to 2 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 4, 2013 · Synced Sep 28, 2026, 7:29 AM EDT
Terminated Not applicable Interventional Results available

Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors

NCT00488644
View directory record Official record
Conditions
Hypothyroidism, Brain Tumor
Interventions
Levothyroxine, Liothyronine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Sep 28, 2026, 7:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Thyroid and Fat Tissue Metabolism

NCT00312715
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 1 Interventional Results available

Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study

NCT02760056
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Liothyronine sodium, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 18, 2018 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 1 Interventional

Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy

NCT01502917
View directory record Official record
Conditions
Brain Cancer, Brain Stem Glioma
Interventions
Radioactive iodine-labeled monoclonal antibody omburtamab, External Beam Radiotherapy
Drug · Radiation
Lead sponsor
Y-mAbs Therapeutics
Industry
Eligibility
2 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Liothyronine Sodium Tablets (50 Mcg) to Cytomel® Tablets (50 Mcg)

NCT00978055
View directory record Official record
Conditions
Healthy
Interventions
1: Liothyronine Sodium Tablets, 2: Cytomel® Tablets
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Sep 15, 2009 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Developing Oral LT3 Therapy for Heart Failure - HFpEF

NCT04111536
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Low Triiodothyronine Syndrome
Interventions
liothyronine, Placebo
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 28, 2026, 7:29 AM EDT
Terminated Phase 1 Interventional

Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to Radiation Therapy

NCT00788307
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ad5-CMV-NIS, Liothyronine Sodium, Reverse Transcriptase Polymerase Chain Reaction, laboratory biomarker analysis, Iodine I 131, Iodine I 123
Biological · Drug · Genetic + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 28, 2026, 7:29 AM EDT
Terminated Phase 2 Interventional Results available

Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma

NCT03787303
View directory record Official record
Conditions
Metastatic Breast Cancer, Thyroid Dysfunction
Interventions
Triiodothyronine (T3)
Drug
Lead sponsor
Aultman Health Foundation
Other
Eligibility
18 Years to 105 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Sep 28, 2026, 7:29 AM EDT
Not yet recruiting Phase 2 Interventional

T4/T3 Therapy in Hypothyroidism

NCT07424183
View directory record Official record
Conditions
Hypothyroidism Primary
Interventions
Liothyronine (L-T3), Levothyroxine Sodium (LT4) Tablets, Liothyronine (LT3) placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 3 Interventional Results available

Liothyronine (T3) for Bipolar Depression

NCT00790738
View directory record Official record
Conditions
Depression, Bipolar Disorder
Interventions
Liothyronine (T3), placebo
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 2 Interventional Results available

Thyroid Hormone to Induce Non-Insulin Mediated Glucose Disposal in People With Insulin Receptor Mutations

NCT02457897
View directory record Official record
Conditions
Insulin Resistance, Diabetes Mellitus, Abnormal Glucose Metabolism
Interventions
Liothyronine
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Sep 28, 2026, 7:29 AM EDT
Active, not recruiting Phase 2 Interventional

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

NCT04743661
View directory record Official record
Conditions
Recurrent Medulloblastoma, Recurrent Ependymoma
Interventions
Irinotecan, Temozolomide, Bevacizumab, Omburtamab I-131, Liothyronine, SSKI, Dexamethasone, Antipyretic, Antihistamine, anti-emetics
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 21 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Los Angeles, California • New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Sustained-Release Liothyronine Sodium (T3) in Healthy Subjects

NCT01581463
View directory record Official record
Conditions
Healthy
Interventions
Liothyronine, Sodium
Drug
Lead sponsor
Ipe, LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2012 · Synced Sep 28, 2026, 7:29 AM EDT
Recruiting Phase 2Phase 3 Interventional

Novel Approaches to the Treatment of Hypothyroidism

NCT06731764
View directory record Official record
Conditions
Hypothyroidism
Interventions
Levothyroxine, Levothyroxine/Liothyronine once daily, Levothyroxine/Liothyronine twice daily
Drug
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin

NCT01182285
View directory record Official record
Conditions
Thyroid Neoplasm
Interventions
Valproic Acid, Liothyronine Sodium
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 1 Interventional

Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer

NCT00004062
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
azacitidine, liothyronine sodium, iodine I 131
Drug · Radiation
Lead sponsor
Lucille P. Markey Cancer Center at University of Kentucky
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Developing Oral LT3 Therapy for Heart Failure - HFrEF

NCT04112316
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction (HFrEF), Low T3 Syndrome
Interventions
Liothyronine, Placebo
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 23, 2024 · Synced Sep 28, 2026, 7:29 AM EDT